Nurix Therapeutics (NASDAQ:NRIX – Get Rating) will release its earnings data on Wednesday, April 5th.
Nurix Therapeutics Stock Down 0.2 %
Shares of NASDAQ NRIX opened at $8.86 on Tuesday. Nurix Therapeutics has a 52 week low of $7.52 and a 52 week high of $19.91. The business has a 50-day simple moving average of $10.08 and a two-hundred day simple moving average of $11.38. The company has a market cap of $420.32 million, a P/E ratio of -2.38 and a beta of 1.69.
Analyst Ratings Changes
Several brokerages have commented on NRIX. Needham & Company LLC cut their target price on Nurix Therapeutics from $32.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, February 10th. HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, March 21st. JPMorgan Chase & Co. dropped their price target on Nurix Therapeutics from $37.00 to $36.00 and set an “overweight” rating for the company in a research report on Monday, February 13th. Stifel Nicolaus dropped their price target on Nurix Therapeutics from $37.00 to $31.00 and set a “buy” rating for the company in a research report on Tuesday, February 14th. Finally, Oppenheimer started coverage on Nurix Therapeutics in a research report on Monday, February 27th. They set an “outperform” rating and a $25.00 price target for the company. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.75.
Institutional Trading of Nurix Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in Nurix Therapeutics by 11.0% in the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company’s stock worth $48,512,000 after buying an additional 367,743 shares in the last quarter. State Street Corp boosted its stake in Nurix Therapeutics by 9.2% in the third quarter. State Street Corp now owns 2,312,224 shares of the company’s stock worth $30,128,000 after buying an additional 195,453 shares in the last quarter. Vanguard Group Inc. boosted its stake in Nurix Therapeutics by 2.3% in the third quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company’s stock worth $28,156,000 after buying an additional 49,370 shares in the last quarter. FMR LLC boosted its stake in Nurix Therapeutics by 59.6% in the second quarter. FMR LLC now owns 1,790,655 shares of the company’s stock worth $22,688,000 after buying an additional 668,632 shares in the last quarter. Finally, Wasatch Advisors Inc. boosted its stake in Nurix Therapeutics by 28.5% in the first quarter. Wasatch Advisors Inc. now owns 1,546,689 shares of the company’s stock worth $21,669,000 after buying an additional 343,100 shares in the last quarter. Hedge funds and other institutional investors own 91.33% of the company’s stock.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Read More
Receive News & Ratings for Nurix Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nurix Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.